NoRD Bio

NoRD Bio is a biotechnology company focused on transforming precision medicine through advanced genomic and transcriptomic analysis. They have developed the SmartRD platform, an ultra-high sensitivity, multi-modal liquid biopsy system that combines ultra-deep sequencing of circulating cell-free DNA (cfDNA) with proprietary AI and machine learning models. This technology is designed to provide comprehensive insights into tumor biology, including subclonal reconstruction, evolutionary trajectory mapping, and the identification of early driver mutations. By integrating methylation data and nucleosome profiling, the company’s platform enables the detection of minimal residual disease and the monitoring of treatment response with high precision.

The company's solutions are designed to address the clinical limitations of invasive biopsies, providing a non-invasive, cost-effective, and easy-to-sample alternative for cancer patients. NoRD Bio is currently advancing research in saliva-based cfDNA assays, specifically targeting head and neck squamous cell carcinoma, with support from the National Cancer Institute. Their services are used by pharmaceutical and biotech companies to optimize cancer drug trials, improve patient stratification, and develop personalized treatment protocols. The company’s expertise is underpinned by a leadership team with extensive backgrounds in cancer computational biology and genomic technology development, supported by research frequently published in leading scientific journals.